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Introduction
Duchenne muscular dystrophy (DMD) is an inherited, X-linked 
recessive condition characterized by progressive weakness and 
loss of skeletal and cardiac muscle.1,2 DMD is caused by muta-
tions in the DMD gene, which codes for the muscle protein dys-
trophin and functions to stabilize muscle fibers.
DMD causes progressive muscle weakness and degenera-
tion, resulting in death in the late second to third decade of life, 
secondary to respiratory or cardiac failure.2 Recent advances in 
clinical DMD care—including use of corticosteroids, improved 
orthopedic intervention, respiratory, and nutritional care—
have resulted in improved quality of life and life expectancy, 
with some individuals living into their fourth decade.3 To slow 
muscle disease progression in DMD, corticosteroids, including 
prednisone and deflazacort, have become standard of care, with 
the latter being the standard of care in many centers because of 
emerging evidence suggesting that deflazacort-treated patients 
experience slower rates of decline in motor outcome scores and 
fewer negative side effects compared to prednisone.4-8
One well-described complication of DMD is low bone 
mineral density (BMD), likely secondary to a constellation of 
low bone mass and deterioration of bone microarchitecture, 
exacerbated by corticosteroid treatment and reduced weight 
bearing associated with this condition.4,9-11 In DMD, even in 
those patients who are ambulatory, BMD decreases signifi-
cantly over time.12-15 This low BMD results in a high incidence 
of fragility fractures, which greatly impairs function and quality 
of life in this population.16,17
Notably, a recent study by Joseph and colleagues demon-
strated that boys with DMD treated with daily deflazacort had 
16-fold increased risk for first fracture.18
Bisphosphonates are widely used in the treatment of child-
hood osteoporosis and fragility fractures.19 Several studies have 
demonstrated reduced frequency of fragility fractures and 
improved BMD after bisphosphonate therapy in pediatric 
patients with osteogenesis imperfecta and osteoporosis.20-24 
However, only small-size studies exist that report on bisphos-
phonate therapy3,25 in pediatric patients with DMD. Two stud-
ies describe oral bisphosphonate therapy in patients with 
DMD.25,26 In these studies of 16 and 52 patients with DMD 
treated with oral alendronate and oral risedronate therapy, 
respectively, total-body BMD remained stable.25,26 In a more 
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recent retrospective study in 7 pediatric DMD patients, intra-
venous (IV) bisphosphonate therapy with either zoledronic 
acid or pamidronate was associated with stabilization of verte-
bral fractures and improvement in vertebral height ratios of 
previously fractured vertebrae.3
In spite of the common use of these medications in this 
population, there is limited data on the impact of IV bisphos-
phonate therapy on BMD and fragility fractures in boys with 
DMD. Therefore, the primary objective of this study was to 
estimate the comparative effectiveness of bisphosphonate ther-
apy on BMD in glucocorticoid-treated DMD patients. The 
study also aimed to describe fragility fractures and ambulatory 




All children in BC and the Yukon, Canada with DMD are fol-
lowed through the multidisciplinary Neuromuscular Clinic at 
British Columbia’s Children’s Hospital (BCCH). The standard 
of care for DMD management is in accordance with recent 
guidelines and includes treatment with corticosteroids, usually 
in the form of deflazacort, from the age of 4 years.27
At BCCH, care for bone health in children with DMD 
involves many disciplines, including pediatric neurology, endo-
crinology, orthopedics, and radiology. All care of boys with 
DMD at BCCH is provided by a single pediatric neurologist 
and medical director of the neuromuscular diseases program. As 
such, steroid dosing and frequency of investigations is consist-
ent among all subjects. Deflazacort is dosed at 0.9 mg/kg/day to 
a maximum dose of 36 mg and prednisone 0.7 mg/kg/day. 
Routine bone health screening includes measuring serum 
25-hydroxyvitamin D twice yearly, lateral thoracolumbar spine 
radiographs every 6-12 months, and BMD assessment with 
dual-energy X-ray absorptiometry (DXA) annually during cor-
ticosteroid treatment. In those patients who are non-ambula-
tory, knee height is used and converted to estimated height.
IV bisphosphonate therapy is routinely used in the endocri-
nology program.28 Standardized dosing for pamidronate is 
1 mg/kg per infusion for 3 days every 4 months, and for zole-
dronic acid is 0.05 mg/kg once every 6 months. More recently, 
the standard of practice has shifted from using pamidronate to 
using zoledronic acid exclusively. For the purposes of this ret-
rospective review at BCCH, the decision to refer to endocri-
nology was at the discretion of the treating neurologist; 
similarly, following referral, the decision to initiate bisphos-
phonate therapy was at the discretion of the treating endocri-
nologist for each study subject.
BMD measurements were completed at BCCH using a 
Hologic Discovery A dual-energy X-ray absorptiometry 
(DXA) machine with software version 13.4.2. BMD is con-
verted to Z-scores (adjusted for age, height and sex) at the lum-
bar, hip and total body measurements. Over the time period of 
this study, BMD scans were used at regular, consistent intervals 
as all children with DMD are cared for by a single pediatric 
neurologist. Furthermore, all BMDs in DMD patients were 
reviewed by a single nuclear medicine radiologist (HN).
Study design
This study was approved by the University of British Columbia 
Clinical Research Ethics Board (H17-03002). This study is a 
retrospective cohort study conducted at BCCH of boys with 
DMD followed by the multidisciplinary neuromuscular clinic 
from 1989 to 2017.
Treated cases were identified as those with DMD who 
received at least one bisphosphonate infusion (pamidronate or 
zoledronic acid) during the study period. An untreated cohort 
of DMD subjects was identified from the BCCH neuromus-
cular clinic database of patients followed for DMD. Those 
included in the analysis were bisphosphonate-treated patients 
who had at least 1 BMD by DXA measured no more than 4 
weeks before and after bisphosphonate treatment, and 
untreated patients who had at least 2 BMDs measurements at 
BCCH. All DXA reported results were completed head out 
(not including skull). Vertebrae with vertebral fractures were 
excluded from the BMD analysis. All DXA scan data at our 
center is corrected for size using the height adjusted Z-score to 
determine height adjusted for age.
Eligible patients’ electronic and paper records were reviewed 
to collect data on subject demographics, past medical history, 
DMD diagnosis and management, physical examination and 
laboratory investigations during treatment, bisphosphonate 
therapy, fragility fractures history prior to and following bis-
phosphonate treatment, and results of BMD by DXA scans. 
These parameters were collected from the first visit to the most 
recent visit at BCCH. In those treated with bisphosphonates, 
data were also collected at the visit prior to the first infusion 
and the visit after the most recent infusion.
All fracture data were collected from the patient imaging 
reports and patient records and included all non-traumatic frac-
tures reported in the patient clinic visits or emergency room visits. 
Each fracture identified in the clinic chart was subsequently con-
firmed in the X-ray report by a pediatric radiologist at our center. 
Fragility fractures were defined as all non-traumatic fractures 
(including vertebrae and long bones). The cumulative number of 
fragility fractures in bisphosphonate-treated subjects was col-
lected from clinic documentation and radiology reports prior to 
receiving bisphosphonate therapy and again from the most recent 
clinic visit. Post-infusion fractures are reported as total fractures 
since initiation of bisphosphonate therapy. In the untreated 
cohort, the number of total fractures was collected prior to first 
DXA scan and at most recent clinic visit. In those subjects where 
the same fracture (for example, a specific vertebral fracture) was 
seen prior to bisphosphonate therapy and again afterwards, it was 
only counted towards fragility fractures prior to therapy start.
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The subject’s height and weight were used to calculate 
body-mass index (BMI), which was converted to a Z-score to 
standardize the measurement for age and gender.29
Statistical Analysis
Descriptive statistics (mean and SD for the continuous varia-
bles, or number and percentage for the categorical variables) 
are presented for the full cohort, and by their treatment status. 
As recommended in the STROBE guidelines, hypothesis test-
ing was not done to compare the intervention groups, and 
hence no P-values are reported.30
Change in BMD was defined as the difference between the 
first and the last BMD measurement in the untreated group, 
and the difference between last BMD measurement (post-bis-
phosphonate) and the BMD measurement immediately prior 
to initiation of bisphosphonate therapy in the treated group. 
Due to the non-randomized nature of the study, we attempted 
to address treatment indication bias within the framework of 
marginal structural models.31 More specifically, we estimated 
the comparative effectiveness of bisphosphonate therapy by 
applying stabilized inverse probability of treatment weights 
(IPTW) in the generalized estimating equations (GEE) mod-
els. We used robust standard errors to accommodate repeated 
measures of BMD. Propensity score was calculated by fitting 
logistic regression models using an a priori list of variables 
including year of DMD diagnosis, and baseline weight, height, 
calcium supplement, fracture, and ambulation status, as the 
predictors of treatment allocation. The balance of the propen-
sity score was visually checked using histograms. The numera-
tor for the stabilization of the IPTW was the marginal 
probability of treatment allocation, estimated by fitting inter-
cept-only logistic regression, for the treated group. The com-
plement of this probability was the numerator for the untreated 
group. Similarly, the propensity score was the denominator for 
the treated group, while the complement of the propensity 
score was the denominator for the untreated group.32 The sta-
bilized IPTW-weighted GEE models were further adjusted 
for baseline values of respective BMD Z-scores to address the 
mathematical phenomenon of regression towards the mean.33 
Time between the first and last BMD measurement was addi-
tionally adjusted in the sensitivity analyses. We plotted the esti-
mated changes in BMD Z-scores in the treated and untreated 
groups, computed at the baseline mean BMD Z-scores in the 
untreated group, to graphically present the predicted trajectory 
of children with and without bisphosphonate therapy. SAS 
software version 9.4 was used for the statistical analysis.34 All 
the tests were two-sided with a significance level of 0.05.
Results
During the study period, 38 boys with DMD were treated with 
bisphosphonates, and 36 boys were not treated. Six bisphos-
phonate-treated subjects were excluded from DXA analysis 
because they did not have DXA scans completed after starting 
treatment. The baseline characteristics of the study population 
are presented in Table 1. Mean (SD) age of DMD diagnosis in 
the entire study population was 4.2 (2.3) years, with a slightly 
lower mean age for those who initiated bisphosphonate ther-
apy. All bisphosphonate-treated subjects were treated with 
daily deflazacort, except for 1 patient who was treated with 
daily prednisone for the duration of the study period. 
Concomitant medications are presented in Table 1 and there 
were no patients treated with either growth hormone or met-
formin. Mean follow-up between the first and the last BMD 
DXA evaluation was 4.4 (2.2) and 4.7 (2.6) years in treated and 
untreated subjects, respectively. Mean (SD) duration of bispho-
sphonate treatment was 4.2 (2.7) years and range was 
12 months—7.5 years. In those treated with bisphosphonates, 7 
(18.4%) were treated with pamidronate, 17 (44.7%) were 
treated with zoledronic acid, and 14 (36.8%) were treated ini-
tially with pamidronate and then switched to zoledronic acid 
(combination). Mean age of initiation of bisphosphonate treat-
ment was 12.8 (2.2) years. The most common documented 
adverse events related to bisphosphonate treatment were chills 
(68.8%), aches (68.8%), numbness/tingling (65.6%), and mus-
cle cramps/spasms (59.4%).
Average number of fragility fractures dropped from 3.5 pre-
bisphosphonate to 1.0 (over mean time period 4.2 years) after 
bisphosphonate therapy (4.4 to 0, 3.0 to 0.9, and 3.5 to 1.7, in 
those treated with pamidronate, zoledronic acid, and a combi-
nation, respectively) (Table 2). This trend was similar when the 
follow-up time was taken into account to calculate the number 
of fractures per year. The average number of fractures per year 
dropped from 2.4 (2.2) to 0.7 (1.2) overall, and 3.6 to 0, 1.6 to 
0.5, and 2.4 to 1.2 in the pamidronate, zoledronic acid, and 
combination group, respectively.
Physical examination parameters, laboratory investigations 
and new fractures for treated and untreated subjects are shown 
in Table 2. Baseline BMI was higher (22.3 vs 18.1 kg/m2) 
among those treated with bisphosphonate therapy compared to 
those who were untreated. Baseline 25-hydroxy vitamin-D lev-
els were higher among the treated (90.8 vs 75.0 nmol/L). All 
subjects were Tanner stage 1 at their first visit (mean age 
12.8 years). In those subjects with Tanner staging available, all 
were below the average Tanner stage for age at the time of bis-
phosphonate initiation. Tanner staging was not performed in 
the untreated group.
The estimates from the stabilized IPTW-weighted GEE 
models additionally adjusting for the respective baseline BMD 
Z-scores are shown in Table 3. The results show that the mean 
decline in BMD measurement was significantly greater in the 
untreated group compared to the treated group. Compared to 
the treated group, the untreated group had an additional 0.63-
SD decrease (95% confidence interval [CI]: −1.18, −0.08, 
P = .026) in total BMD and an additional 1.04-SD decrease 
(95% CI: −1.74, −0.34; P = .004) in the left hip BMD, but the 
change in lumbar spine BMD (0.15, 95% CI: −0.36, +0.66; 
P = .57) was not statistically significant. These estimates were 
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unchanged when further adjusted for the time between first and 
last BMD measurement (Table 3).
Figure 1 depicts the change in BMD between the first and 
last measurement, computed using the baseline mean Z-scores. 
In this analysis, a steeper decline in BMD was found in the 
untreated group compared to the treated group.
Discussion
This is the first study to describe changes in BMD in boys with 
corticosteroid-treated DMD treated with bisphosphonates, 
compared to not treated natural controls. Our data demon-
strate a greater deterioration in BMD assessed by DXA based 
on 2 measurements in those who did not receive bisphospho-
nates compared to those who did. This suggests that bisphos-
phonates may help prevent reduction of BMD over time in 
corticosteroid-treated DMD.
In a similar study, Houston and colleagues compared 
patients with DMD who received glucocorticoids to those 
who did not, and their results demonstrated a significant 
decrease in BMD in those who received glucocorticoids.35 In 
a sub-analysis of this population, oral alendronate was asso-
ciated with stabilization of hip BMD. Currently, a placebo-
controlled study is underway evaluating IV zolendronate in 
children with DMD, although these results are not yet avail-
able (unpublished data; ClinicalTrials.gov Identifier: 
NCT00799266).
In our study, many of the subjects were prepubertal, and 
therefore their BMD Z-scores are likely reading lower than 
their healthy age peers who are in puberty. Unfortunately, we 
were not able to compare this data to healthy controls to eval-
uate this further. Pubertal status is important in the interpre-
tation of BMD. It is likely that, similar to our center, many 
Table 1. Baseline characteristics of the study population in the study on the effectiveness of bisphosphonate therapy on bone mineral density in 
boys with Duchenne muscular dystrophy.a
TREATED (N = 32) UNTREATED (N = 36)
Age at diagnosis (years) 3.6 (1.9) 4.8 (2.4)
Age at steroid start (years) 4.2 (1.89) 4.9 (1.78)
Age at bisphosphonate start (years) 12.7 (2.17) NA
Total bisphosphonate infusions 9.9 (7.3) NA
Calcium supplementation; n (%) 15 (46.9) 26 (72.2)
Vitamin D supplementation; n (%) 32 (100.0) 36 (100.0)
Deflazacort treatment; n (%) 32 (100) 35 (97.2)
Duration of bisphosphonate therapy; (years) 4.2 (2.7) NA
Time between first and last BMD measurement; (years) 4.4 (2.2) 4.7 (2.6)
Other medications
 Beta blockersb; n (%) 8 (25.0) 8 (22.2)
 ACE inhibitorsc; n (%) 21 (65.6) 11 (30.6)
 Antidepressantsd; n (%) 11 (34.4) 4 (11.1)
 Stimulantse; n (%) 4 (12.5) 4 (11.1)
 Coenzyme Q; n (%) 0 (0) 4 (11.1)
 Digoxin; n (%) 3 (9.4) 3 (8.3)
 Losartan; n (%) 1 (3.1) 0 (0)
 Testosterone; n (%) 2 (6.3) 0 (0)
 Ranitidine/omeprazole; n (%) 1 (3.1) 0 (0)
 Ataluren; n (%) 1 (3.1) 1 (2.8)
Abbreviations: ACE, angiotensin converting enzyme; NA, not applicable; SD, standard deviation.
aData presented as mean (SD) unless otherwise specified.
bBeta blockers include carvedilol, bisoprolol, and metoprolol.
cACE inhibitors include ramipril and enalapril.
dAntidepresants include sertraline, citalopram, trazodone, fluoxetine, and escitalopram.
eStimulants include atomoxetine and methylphenidate.
Ronsley et al 5
Table 2. Changes in anthropometric, laboratory, fracture and radiographic measurements in boys managed with and without bisphosphonate therapy.a
TREATED (N = 32) UNTREATED (N = 36)
 FIRST RECENT FIRST RECENT
PHySICAL ExAMINATIONb
Height ⩽3rd centilec; n (%) 5 (21.7) 22 (88.0) 10 (41.7) 21 (61.8)
Weight ⩽3rd centilec; n (%) 4 (16.0) 8 (32.0) 5 (14.3) 7 (21.2)
BMI 22.3 (5.4) 26.4 (8.2) 18.1 (4.7) 23.7 (5.3)
BMI ⩾90th centilec; n (%) 7 (21.9) 11 (34.4) 5 (13.9) 18 (50.0)
BMI ⩾95th centilec; n (%) 5 (15.6) 9 (28.1) 5 (13.9) 17 (47.2)
Tanner staging
Performed; n (%) 13 (40.6) 11 (34.4)  
 1; n (%) 13 (100.0) 5 (45.5)  
 2; n (%) 0 (0) 3 (27.3)  
 3-5; n (%) 0 (0) 3 (27.3)  
Unknown; n (%) 19 (59.4) 21 (65.6)  
LABORATORy VALUES
Ionized calcium (mmol/L) 1.2 (0.0) 1.14 (0.04) 1.2 (0.1) 1.12 (0.07)
25-hydroxyvitamin D (nmol/L) 90.8 (37.8) 102.0 (32.14) 75.0 (58.9) 94.4 (50.27)
Total calcium (mmol/L) 2.3 (0.1) 2.29 (0.14) 2.4 (0.1) 2.35 (0.08)
Alkaline phosphatase (U/L) 67.1 (23.0) 54.8 (17.11) 82.5 (27.1) 78.6 (26.00)
Creatinine (µmol/L) 25.2 (8.6) 23.1 (8.32) 24.9 (11.9) 22.2 (5.56)
Urine Ca/Cr ratio 1.70 (1.7) 1.23 (0.93) 1.9 (1.8) 1.67 (1.11)
TOTAL FRACTURES
Pamidronate (n = 7) 4.4 (2.8) 0 (0.0)  
Zoledronic acid (n = 12) 3.0 (2.7) 0.9 (1.5)  
Combinationd (n = 13) 3.5 (3.3) 1.7 (2.3)  
Cumulative fractures (n) 112 33 33 73
Fractures per subject 3.5 (2.9) 1.0 (1.8) 0.9 (1.1) 2.0 (2.1)
Non-ambulatory; n (%) 17 (53.1) 23 (71.9) 22 (61.1) 30 (83.3)
Ambulatory; n (%) 15 (46.9) 9 (28.1) 14 (38.9) 6 (16.7)
BMD Z-SCORES
Left hip –4.6 (1.3) –4.3 (1.0) –2.9 (1.4) –4.1 (1.0)
L1-L4 –2.3 (0.9) –2.6 (1.0) –1.3 (1.2) –1.9 (0.9)
First = first clinic visit to the Endocrinology Clinic; Recent = most recent clinic visit at the time of data analysis.
Abbreviations: AAP, American Academy of Pediatrics; BMD, bone mineral density; BMI, body mass index; SD, standard deviation.
aData presented as mean (SD) unless otherwise specified.
bUnknown values were omitted from percent calculations.
cHeight, weight, and BMI for age centiles were categorized as per the Centers for Disease Control29.
dCombination includes pamidronate followed by zoledronic acid.
neurologists specializing in the care of DMD patients feel it is 
outside of their competence to perform these pubertal exams. 
These data highlight the need for systematic 
pubertal evaluation in boys with DMD, and the importance of 
collaborative care between neurology and endocrinology 
regardless of whether bisphosphonate treatment will be used.
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Our data also show a reduction in the number of fragility 
fractures following treatment with both pamidronate and zole-
dronic acid. It is possible that fragility fractures reduction is, in 
part, related to subjects’ reduction in ambulation. Unfortunately, 
we were not able to assess the relationship between reduction in 
fragility fracture and change in ambulatory status. In a study in 7 
boys with DMD, Sbrocchi and colleagues found an improve-
ment in both vertebral height and pain following 2 years of treat-
ment with either pamidronate or zoledronic acid, suggesting a 
reduction in vertebral compression fractures.3 As these fractures 
are often associated with significant pain, treatment resulting in 
fracture reduction is an important contributor to improving 
patient quality of life. In fact, we noted as part of this retrospec-
tive review that 100% of the bisphosphonate-treated subjects’ 
physicians commented in their medical records on “reduction in 
pain” following initiation of bisphosphonate treatment.
Limitations and strengths
The main limitation of this study is its retrospective nature, and 
thus it is restricted to the data available in the patient record. For 
example, Tanner staging was not available in untreated subjects 
because these patients were not assessed by endocrinology. In 
addition, the decision to start bisphosphonate treatment was at 
the discretion of the treating endocrinologist, and therefore var-
ied by study subject. Furthermore, there were several bisphospho-
nate-treated subjects who did not have a calcium supplement 
recorded in the patient record despite endocrine clinic recom-
mendations for use, which may have led to under reporting of this 
supplement in this study. Another limitation of this study is that 
it was not feasible to re-review spine radiographs with a single 
radiologist completed over the course of the last 20 years. Spine 
fracture data was collected from the radiology report, all of which 
were generated by a pediatric radiologist at the time of fracture 
diagnosis. There may have been some variation in the interpreta-
tion of these films over the years, and because of the retrospective 
nature of the study, the radiologist at the time may not have been 
blinded to the treatment status. As well, since the average number 
of fractures before and after BMD therapy are likely affected by 
Table 3. Change in the mean BMD Z-score (total body, left hip, and lumbar) among boys with DMD estimated from the generalized estimating 
equations models weighted by the stabilized inverse probability of treatment weights.
CHARACTERISTICS BMD TOTAL BMD LEFT HIP BMD LUMBAR SPINE
 MEAN (95% CI) P VALUE MEAN (95% CI) P VALUE MEAN (95% CI) P VALUE
BMD Z-score change in the 
untreated compared to the treated*
–0.63 (–1.18, –0.08) .026 –1.04 (–1.74, –0.34) .004 0.15 (–0.36, 0.66) .570
BMD Z-score change in the 
untreated compared to the treated**
–0.62 (–1.18, –0.07) .028 –1.04 (–1.75, –0.34) .004 0.15 (–0.37, 0.66) .577
Abbreviations: BMD, bone mineral density; CI, confidence interval; DMD, Duchenne muscular dystrophy.
*Estimates from the generalized estimating equations model using stabilized inverse probability of treatment weights, and further adjusting for the respective baseline BMD 
Z-scores.
**Previous models but additionally adjusting for time between the first and the last BMD measurements.
Figure 1. Comparative effectiveness of bisphosphonate treatment on 
bone mineral density in children with Duchenne muscular dystrophy 
estimated from the generalized estimating equations weighted by the 
stabilized inverse probability of treatment weights and adjusting for the 
respective baseline BMD Z-scores.
A: Total BMD Z-score; B: Left hip BMD Z-score; C: Lumbar spine BMD Z-score 
BMD, bone mineral density.
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variable follow-up time, we further compared the number of frac-
tures per year, and the primary findings remained unaffected. 
However, owing to the retrospective nature of the data, it was 
challenging to precisely estimate the follow-up time, especially 
for the control group, because patients were not followed up with 
a pre-specified schedule. Furthermore, we were not able to objec-
tively quantify changes in pain or quality of life, as no objective 
pain rating scale was used consistently. Nevertheless, physicians 
documented a subjective improvement in pain in 100% of treated 
subjects’ medical records. Furthermore, a strength of this study is 
that all boys with DMD are cared for by a single neurologist and 
thus glucocorticoid dosing is consistent. Another potential limi-
tation includes the non-randomized nature of the data which are 
subject to treatment indication bias and residual confounding. 
However, we attempted to address the issue of treatment indica-
tion bias by applying a sophisticated analytic strategy, stabilized 
IPTW-weighted GEE models, additionally adjusting for the 
baseline outcome values to address the mathematical phenome-
non of regression towards the mean. In our analysis, the estimates 
were robust and are further adjusted for time between the first 
and last BMD measurement.
Despite its limitations, this is the largest study to date describ-
ing BMD assessed by DXA in boys with corticosteroid-treated 
DMD. Furthermore, this is the first study to compare boys with 
DMD treated with bisphosphonates to those who were not 
treated using robust methodological and analytic strategies.
Conclusion
Bisphosphonate therapy may be associated with a slower 
decline in BMD in boys with corticosteroid-treated DMD. 
Fragility fractures were substantially reduced following bis-
phosphonate therapy in this cohort. Prospective longitudinal 
studies systematically evaluating BMD and fragility fractures, 
as well as objective measures of pain and quality of life, follow-
ing bisphosphonate therapy are needed. Furthermore, studies 
with the newer dissociative corticosteroids such as vamorolone 
or other glucocorticoid-sparing treatments for DMD are 
needed to protect against the rapid BMD decline in this vul-
nerable population.
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